$999 Million is the total value of EcoR1 Capital, LLC's 54 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 138.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARGX | New | ARGENX SEsponsored adr | $79,266,000 | – | 825,087 | +100.0% | 7.93% | – |
| KURA | Buy | KURA ONCOLOGY INC | $74,086,000 | +8.5% | 5,276,753 | +35.2% | 7.41% | +20.5% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $55,750,000 | -41.3% | 5,381,282 | +4.7% | 5.58% | -34.8% |
| ONCE | Buy | SPARK THERAPEUTICS INC | $44,496,000 | -2.6% | 1,136,851 | +35.8% | 4.45% | +8.2% |
| IONS | Buy | IONIS PHARMACEUTICALS INC | $39,211,000 | +951.0% | 725,326 | +902.9% | 3.92% | +1067.6% |
| Buy | FIBROGEN INCcall | $38,912,000 | +83.0% | 840,800 | +140.2% | 3.89% | +103.2% | |
| XNCR | New | XENCOR INC | $35,763,000 | – | 989,018 | +100.0% | 3.58% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $27,453,000 | – | 647,169 | +100.0% | 2.75% | – |
| SLDB | New | SOLID BIOSCIENCES INC | $23,242,000 | – | 867,246 | +100.0% | 2.33% | – |
| New | ASCENDIS PHARMA A Sput | $22,554,000 | – | 360,000 | +100.0% | 2.26% | – | |
| EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $16,212,000 | +30.0% | 1,595,643 | +53.5% | 1.62% | +44.3% |
| SGMO | Buy | SANGAMO THERAPEUTICS INC | $13,613,000 | +134.0% | 1,185,831 | +245.5% | 1.36% | +159.9% |
| ZLAB | Buy | ZAI LAB LTDsponsored adr | $13,221,000 | +93.9% | 569,377 | +62.7% | 1.32% | +115.5% |
| ABUS | Buy | ARBUTUS BIOPHARMA CORP | $12,568,000 | +8.0% | 3,281,502 | +166.4% | 1.26% | +19.9% |
| Buy | IRONWOOD PHARMACEUTICALS INCcall | $12,145,000 | +15.9% | 1,172,300 | +106.5% | 1.22% | +28.7% | |
| MYOK | New | MYOKARDIA INC | $11,452,000 | – | 234,381 | +100.0% | 1.15% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $10,775,000 | – | 400,838 | +100.0% | 1.08% | – |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $9,835,000 | +338.7% | 233,933 | +421.7% | 0.98% | +387.1% |
| SURF | Buy | SURFACE ONCOLOGY INC | $9,588,000 | -35.7% | 2,261,328 | +65.8% | 0.96% | -28.6% |
| ARRY | New | ARRAY BIOPHARMA INC | $9,177,000 | – | 644,002 | +100.0% | 0.92% | – |
| PRTA | New | PROTHENA CORP PLC | $8,634,000 | – | 838,219 | +100.0% | 0.86% | – |
| IMDZ | Buy | IMMUNE DESIGN CORP | $7,284,000 | -5.8% | 5,603,191 | +149.9% | 0.73% | +4.6% |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $6,669,000 | – | 450,000 | +100.0% | 0.67% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $4,838,000 | – | 247,858 | +100.0% | 0.48% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $4,535,000 | – | 613,728 | +100.0% | 0.45% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $3,039,000 | – | 326,775 | +100.0% | 0.30% | – |
| CORT | New | CORCEPT THERAPEUTICS INC | $2,218,000 | – | 166,005 | +100.0% | 0.22% | – |
| CRIS | New | CURIS INC | $2,057,000 | – | 2,982,208 | +100.0% | 0.21% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $1,282,000 | – | 140,118 | +100.0% | 0.13% | – |
| AFMD | New | AFFIMED N V | $492,000 | – | 158,221 | +100.0% | 0.05% | – |
| PRQR | New | PROQR THERAPEUTICS N V | $174,000 | – | 11,022 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-31 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.